gyki 52466 has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzilotti, KF; Jackson, PF; Rissolo, KC; Stauch Slusher, B | 1 |
| Gacsalyi, I; Harsing, LG; Juranyi, Z; Levay, G; Marko, B; Megyeri, K; Sziray, N | 1 |
2 other study(ies) available for gyki 52466 and oxidopamine
| Article | Year |
|---|---|
Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Male; Mesencephalon; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra | 1995 |
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Functional Laterality; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2007 |